Back to search results

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma · Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UAB Medicine - UAB Hospital, Birmingham, Alabama, United States

  • START Los Angeles, Los Angeles, California, United States

  • Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis, Indiana, United States

  • START Midwest, Grand Rapids, Michigan, United States

  • START New York, Lake Success, New York, United States

  • Duke Cancer Center Durham, Durham, North Carolina, United States

  • Next Oncology - Austin, Austin, Texas, United States

  • Next Oncology - Houston, Houston, Texas, United States

  • Next Oncology - Dallas, Irving, Texas, United States

  • START San Antonio, San Antonio, Texas, United States

  • START Mountain Region, West Valley City, Utah, United States

  • National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

  • National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

Study leads

  • Study Physician

    Study Director

    Astellas Pharma Global Development, Inc.

View source on ClinicalTrials.gov(opens in a new tab)